Inactivation of cytomegalovirus in platelet concentrates using Helinx technology.

  • Lin Lin
  • Published 2001 in Seminars in hematology


Cytomegalovirus (CMV) infection in immunocompromised patients may result in severe morbidity and mortality. The standard of care for these patients is the use of CMV-seronegative blood components. Alternatively, filtered, leukocyte-reduced blood components have been used. However, neither approach completely prevented transfusion-associated CMV infection in… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.